Boston Scientific Corp. (BSX)

$90.75

+0.54

(+0.6%)▲

Market is closed - opens 8 PM, 29 Nov 2024

Performance

  • $90.08
    $90.99
    $90.75
    downward going graph

    0.74%

    Downside

    Day's Volatility :1.0%

    Upside

    0.26%

    downward going graph
  • $53.93
    $91.93
    $90.75
    downward going graph

    40.57%

    Downside

    52 Weeks Volatility :41.34%

    Upside

    1.28%

    downward going graph

Returns

PeriodBoston Scientific Corp.Sector (Health Care)S&P500
3 Months
14.12%
-5.7%
7.3%
6 Months
20.73%
3.0%
13.1%
1 Year
65.21%
13.4%
31.7%
3 Years
135.16%
11.4%
30.6%

Highlights

Market Capitalization
133.0B
Book Value
$14.05
Earnings Per Share (EPS)
1.21
PE Ratio
74.55
PEG Ratio
1.62
Wall Street Target Price
96.999
Profit Margin
11.26%
Operating Margin TTM
17.06%
Return On Assets TTM
4.9%
Return On Equity TTM
8.92%
Revenue TTM
15.9B
Revenue Per Share TTM
10.83
Quarterly Revenue Growth YOY
19.3%
Gross Profit TTM
8.7B
EBITDA
4.1B
Diluted Eps TTM
1.21
Quarterly Earnings Growth YOY
-0.06
EPS Estimate Current Year
2.46
EPS Estimate Next Year
2.79
EPS Estimate Current Quarter
0.59
EPS Estimate Next Quarter
0.64

Analyst Recommendation

Buy
    91%Buy
    8%Hold
    0
    0%Sell
Based on 37 Wall street analysts offering stock ratings for Boston Scientific Corp.(by analysts ranked 0 to 5 stars)
Based on 37 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
34
33
31
Hold
3
4
5
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 6.89%

Current $90.75
Target $97.00

Company Financials

FY18Y/Y Change
Revenue
9.8B
↑ 8.57%
Net Income
1.7B
↑ 1506.73%
Net Profit Margin
17.01%
↑ 15.86%
FY19Y/Y Change
Revenue
10.7B
↑ 9.28%
Net Income
4.7B
↑ 181.27%
Net Profit Margin
43.78%
↑ 26.77%
FY20Y/Y Change
Revenue
9.9B
↓ 7.66%
Net Income
-140.0M
↓ 102.98%
Net Profit Margin
-1.41%
↓ 45.19%
FY21Y/Y Change
Revenue
11.9B
↑ 19.92%
Net Income
1.0B
↓ 843.57%
Net Profit Margin
8.76%
↑ 10.17%
FY22Y/Y Change
Revenue
12.7B
↑ 6.68%
Net Income
698.0M
↓ 32.95%
Net Profit Margin
5.5%
↓ 3.26%
FY23Y/Y Change
Revenue
14.2B
↑ 12.29%
Net Income
1.6B
↑ 128.22%
Net Profit Margin
11.19%
↑ 5.69%
Q2 FY23Q/Q Change
Revenue
3.6B
↑ 6.2%
Net Income
270.0M
↓ 14.01%
Net Profit Margin
7.5%
↓ 1.77%
Q3 FY23Q/Q Change
Revenue
3.5B
↓ 2.0%
Net Income
504.0M
↑ 86.67%
Net Profit Margin
14.29%
↑ 6.79%
Q4 FY23Q/Q Change
Revenue
3.7B
↑ 5.61%
Net Income
505.0M
↑ 0.2%
Net Profit Margin
13.56%
↓ 0.73%
Q1 FY24Q/Q Change
Revenue
3.9B
↑ 3.52%
Net Income
492.0M
↓ 2.57%
Net Profit Margin
12.76%
↓ 0.8%
Q2 FY24Q/Q Change
Revenue
4.1B
↑ 6.85%
Net Income
324.0M
↓ 34.15%
Net Profit Margin
7.86%
↓ 4.9%
Q3 FY24Q/Q Change
Revenue
4.2B
↑ 2.16%
Net Income
468.0M
↑ 44.44%
Net Profit Margin
11.12%
↑ 3.26%
FY18Y/Y Change
Total Assets
21.0B
↑ 10.28%
Total Liabilities
12.3B
↑ 2.02%
FY19Y/Y Change
Total Assets
30.6B
↑ 45.56%
Total Liabilities
16.7B
↑ 35.97%
FY20Y/Y Change
Total Assets
30.8B
↑ 0.7%
Total Liabilities
15.5B
↓ 7.41%
FY21Y/Y Change
Total Assets
32.2B
↑ 4.72%
Total Liabilities
15.6B
↑ 1.01%
FY22Y/Y Change
Total Assets
32.5B
↑ 0.74%
Total Liabilities
14.9B
↓ 4.56%
FY23Y/Y Change
Total Assets
35.1B
↑ 8.21%
Total Liabilities
15.6B
↑ 4.77%
Q2 FY23Q/Q Change
Total Assets
33.6B
↑ 2.16%
Total Liabilities
15.1B
↑ 2.25%
Q3 FY23Q/Q Change
Total Assets
34.0B
↑ 1.32%
Total Liabilities
14.9B
↓ 1.34%
Q4 FY23Q/Q Change
Total Assets
35.1B
↑ 3.21%
Total Liabilities
15.6B
↑ 4.64%
Q1 FY24Q/Q Change
Total Assets
36.7B
↑ 4.36%
Total Liabilities
16.5B
↑ 5.73%
Q2 FY24Q/Q Change
Total Assets
37.1B
↑ 1.2%
Total Liabilities
16.5B
↓ 0.02%
Q3 FY24Q/Q Change
Total Assets
38.1B
↑ 2.61%
Total Liabilities
17.1B
↑ 3.78%
FY18Y/Y Change
Operating Cash Flow
310.0M
↓ 78.26%
Investing Cash Flow
-1.9B
↑ 90.2%
Financing Cash Flow
1.4B
↑ 1201.82%
FY19Y/Y Change
Operating Cash Flow
1.8B
↑ 492.26%
Investing Cash Flow
-5.0B
↑ 162.42%
Financing Cash Flow
3.0B
↑ 107.61%
FY20Y/Y Change
Operating Cash Flow
1.5B
↓ 17.86%
Investing Cash Flow
-411.0M
↓ 91.85%
Financing Cash Flow
293.0M
↓ 90.14%
FY21Y/Y Change
Operating Cash Flow
1.9B
↑ 24.01%
Investing Cash Flow
-1.6B
↑ 288.56%
Financing Cash Flow
-95.0M
↓ 132.42%
FY22Y/Y Change
Operating Cash Flow
1.5B
↓ 18.4%
Investing Cash Flow
-2.0B
↑ 25.92%
Financing Cash Flow
-548.0M
↑ 476.84%
Q2 FY23Q/Q Change
Operating Cash Flow
658.0M
↑ 246.32%
Investing Cash Flow
-840.0M
↑ 73.55%
Financing Cash Flow
43.0M
↓ 162.32%
Q3 FY23Q/Q Change
Operating Cash Flow
698.0M
↑ 6.08%
Investing Cash Flow
-1.5B
↑ 81.07%
Financing Cash Flow
16.0M
↓ 62.79%

Technicals Summary

Sell

Neutral

Buy

Boston Scientific Corp. is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Boston Scientific Corp.
Boston Scientific Corp.
7.07%
20.73%
65.21%
135.16%
109.83%
Stryker Corporation
Stryker Corporation
9.03%
14.39%
32.91%
59.4%
89.47%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
5.18%
-17.2%
7.41%
-34.9%
-11.73%
Abbott Laboratories
Abbott Laboratories
4.28%
16.67%
16.55%
-7.09%
39.2%
Medtronic Plc
Medtronic Plc
-4.78%
5.21%
9.72%
-21.77%
-22.55%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Boston Scientific Corp.
Boston Scientific Corp.
74.55
74.55
1.62
2.46
0.09
0.05
NA
14.05
Stryker Corporation
Stryker Corporation
41.86
41.86
2.72
12.06
0.19
0.07
0.01
52.86
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
27.83
27.83
6.56
2.53
0.19
0.11
NA
16.18
Abbott Laboratories
Abbott Laboratories
35.85
35.85
2.29
4.68
0.15
0.06
0.02
22.94
Medtronic Plc
Medtronic Plc
29.55
29.55
1.63
5.2
0.08
0.04
0.03
37.39
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Boston Scientific Corp.
Boston Scientific Corp.
Buy
$133.0B
109.83%
74.55
11.26%
Stryker Corporation
Stryker Corporation
Buy
$148.6B
89.47%
41.86
16.34%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
Buy
$42.5B
-11.73%
27.83
65.86%
Abbott Laboratories
Abbott Laboratories
Buy
$204.6B
39.2%
35.85
13.99%
Medtronic Plc
Medtronic Plc
Buy
$110.3B
-22.55%
29.55
12.06%

Insights on Boston Scientific Corp.

  • Increasing Revenue

    Revenue is up for the last 5 quarters, 3.52B → 4.20B (in $), with an average increase of 4.3% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, 324.0M → 468.0M (in $), with an average increase of 30.8% per quarter

Institutional Holdings

  • FMR Inc

    9.17%

  • Vanguard Group Inc

    8.91%

  • BlackRock Inc

    8.58%

  • State Street Corp

    4.17%

  • Morgan Stanley - Brokerage Accounts

    2.57%

  • PRIMECAP Management Company

    2.57%

Company Information

Boston Scientific Corp. engages in the development, manufacture and marketing of medical devices that are used in interventional medical procedures. It operates through the MedSurg and Cardiovascular segments.

Organization
Boston Scientific Corp.
Employees
48000
CEO
Mr. Michael F. Mahoney
Industry
Health Technology

FAQs